3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
14
HER2-positive Breast Cancer
4
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Salivary Gland Neoplasms
1
Non-squamous NSCLC
1
Non Small Cell Lung
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
1
Breast Cancer Invasive
1
Breast Cancer Female
1
Advanced Digestive System Tumor
1
Advanced Breast Cancer
1
Interventions
Carboplatin
5
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
sarilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
pyrotinib
×
1 year
×
Clear all
No trials found.